Wells Fargo & Company Issues Pessimistic Forecast for LeMaitre Vascular (NASDAQ:LMAT) Stock Price

LeMaitre Vascular (NASDAQ:LMAT) had its price objective dropped by investment analysts at Wells Fargo & Company from $97.00 to $93.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 7.12% from the company’s current price.

A number of other research firms have also recently issued reports on LMAT. Roth Capital reaffirmed a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a report on Wednesday. Cantor Fitzgerald boosted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Finally, Barrington Research reissued an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $86.82 on Friday. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $109.58. The company has a 50 day moving average of $89.58 and a 200-day moving average of $87.02. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 42.15, a PEG ratio of 2.29 and a beta of 0.77.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business had revenue of $61.05 million for the quarter, compared to analyst estimates of $62.18 million. During the same period in the prior year, the company earned $0.49 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, equities analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director John A. Roush sold 6,561 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the sale, the director directly owned 2,916 shares of the company’s stock, valued at $269,875.80. The trade was a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the transaction, the director directly owned 17,976 shares in the company, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently made changes to their positions in the stock. Geneva Capital Management LLC boosted its holdings in LeMaitre Vascular by 6.0% during the second quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock worth $76,010,000 after buying an additional 51,489 shares during the last quarter. Congress Asset Management Co. raised its position in shares of LeMaitre Vascular by 2.7% in the 3rd quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock valued at $60,580,000 after acquiring an additional 18,298 shares during the period. First Trust Advisors LP boosted its stake in LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after acquiring an additional 211,280 shares during the last quarter. Geode Capital Management LLC grew its holdings in LeMaitre Vascular by 3.0% during the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier’s stock valued at $43,174,000 after purchasing an additional 15,036 shares during the period. Finally, Northern Trust Corp increased its stake in LeMaitre Vascular by 5.4% in the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock valued at $28,993,000 after purchasing an additional 17,748 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.